bristol-myers squibb co (BMY) Key Developments
Bristol-Myers Squibb Company to Present New Data from its Immuno-Oncology Clinical Development Programs
Sep 2 15
Bristol-Myers Squibb Company announced that new data from its Immuno-Oncology clinical development programs to be presented at the 16thWorld Conference on Lung Cancer in Denver, CO from September 6 to 9. The company is presenting Opdivo (nivolumab)data in a broad set of patients with lung cancer, across histologies and treatment settings. These data add to the growing body of evidence that may help the scientific community advance their understanding Opdivo’s role in the treatment of lung cancer as a single agent and its potential in combination with Yervoy (ipilimumab).
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute sign Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies
Aug 31 15
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. QIMR Berghofer Medical Research Institute is a translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders. Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration.
Bristol-Myers Squibb Promotes Betty Edery to the Post of General Counsel for France
Aug 27 15
Bristol-Myers Squibb has promoted Betty Edery to the post of general counsel for France, just over a year after making its last local head of legal appointment. Edery, who was formerly senior legal counsel for Bristol-Myers Squibb France, takes over from Alexandra de Rambuteau as general counsel and a member of the executive committee. De Rambuteau was appointed as general counsel in June last year. It is not known why she is leaving the company or where her next destination is. Edery joined Bristol-Myers Squibb in January 2013, having previously worked for Hogan Lovells in Paris for seven years as a corporate and regulatory lawyer specialising in the pharmaceutical sector.
FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib)
Aug 13 15
Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel® (dasatinib) product labeling. The labeling now includes five-year efficacy and safety data in adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and seven-year data in CP Ph+ CML patients who are resistant1 or intolerant2 to prior therapy, including Gleevec®3 (imatinib mesylate). Sprycel is associated with the following warnings and precautions: myelosuppression, bleeding-related events, fluid retention, cardiovascular events, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, and embryo-fetal toxicity.
Bristol-Myers Squibb Introduces I-O RPM Program in US
Aug 12 15
Bristol-Myers Squibb Company has introduced the Immuno-Oncology Rare Population Malignancy, or I-O RPM, program in the US. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. As part of the I-O RPM program, Bristol-Myers Squibb, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) are pleased to announce that they have entered into a collaboration agreement. The Lurie Cancer Center and NMDTI will conduct a range of early phase clinical studies and Bristol-Myers Squibb will fund positions within the NMDTI Developmental Therapeutics Fellowship program.